Literature DB >> 8299671

Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage.

C R Kumana1, M Kou, Y L Yu, K Y Fong, C F Fung, C M Chang, W Mück, I J Lauder.   

Abstract

Nimodipine pharmacokinetics was investigated in 12 Chinese patients with acute subarachnoid haemorrhage receiving an IV infusion of 1.6 or 2 mg/h (based on estimated body weight) for 10 days. Peripheral venous blood samples were collected for up to 4 days and plasma nimodipine was assayed by GC/ECD. The mean value was taken as the steady state concentration (Css) and Clearance (CL) (hourly dose/Css) was calculated. Eight survivors were given oral nimodipine (60 or 90 mg) every 6h (based on body weight), blood was sampled over 6 h and the plasma nimodipine level determined. The values for Css, CL and CL.kg-1 were 33.5 micrograms.l-1, 58 l.h-1 and 1.0 l.h-1 x kg-1 respectively; in survivors receiving the drug orally, bioavailability of the 30 mg tablet was 9%. In one very sick patient given crushed tablets by naso-gastric tube, the AUC was very low; in vitro studies indicated that adsorption of nimodipine by the tubing was unlikely to have been the cause. The pharmacokinetic findings in Chinese patients are comparable to previously reported values in Caucasians.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8299671     DOI: 10.1007/BF00265956

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine.

Authors:  K D Rämsch; K H Graefe; D Scherling; J Sommer; R Ziegler
Journal:  Am J Nephrol       Date:  1986       Impact factor: 3.754

2.  Alterations in drug distribution and clearance due to obesity.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

3.  Differences in diazepam pharmacokinetics in Chinese and white Caucasians--relation to body lipid stores.

Authors:  C R Kumana; I J Lauder; M Chan; W Ko; H J Lin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage.

Authors:  K D Rämsch; G Ahr; D Tettenborn; L M Auer
Journal:  Neurochirurgia (Stuttg)       Date:  1985-05

Review 5.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

6.  Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E Vinge; K E Andersson; L Brandt; B Ljunggren; L G Nilsson; S Rosendal-Helgesen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Nimodipine treatment of subarachnoid hemorrhage.

Authors:  J Laursen; F Jensen; E Mikkelsen; P Jakobsen
Journal:  Clin Neurol Neurosurg       Date:  1988       Impact factor: 1.876

8.  Nimodipine: synthesis and metabolic pathway.

Authors:  H Meyer; E Wehinger; F Bossert; D Scherling
Journal:  Arzneimittelforschung       Date:  1983

9.  Prevention of symptomatic vasospasm by topically applied nimodipine.

Authors:  L M Auer; Z Ito; A Suzuki; H Ohta
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

10.  Clinical pharmacokinetics of nimodipine in normal and impaired renal function.

Authors:  W Kirch; K D Rämsch; U Dührsen; E E Ohnhaus
Journal:  Int J Clin Pharmacol Res       Date:  1984
  10 in total
  2 in total

1.  Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.

Authors:  F Seker; J Hesser; M A Brockmann; E Neumaier-Probst; C Groden; R Schubert; C Brockmann
Journal:  Clin Neuroradiol       Date:  2015-09-08       Impact factor: 3.649

Review 2.  Nimodipine Pharmacokinetic Variability in Various Patient Populations.

Authors:  Sherif Hanafy Mahmoud; Xinqi Ji; Fadumo Ahmed Isse
Journal:  Drugs R D       Date:  2020-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.